Tanezumab ELISA Kit

Tanezumab (RN624) is a recombinant humanized anti- nerve growth factor (NGF) monoclonal antibody (IgG2 type) that works by inhibiting the binding of NGF to its receptors. It was developed by Pfizer as a treatment for pain.

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.